Baxter, Inc / Hospira UK Limited’s compounding business and related assets merger inquiry

The CMA investigated and cleared the anticipated acquisition by Baxter, Inc of Hospira UK Limited’s ‘compounding’ business and related assets. Compounding is the process of combining, mixing or altering ingredients to create a medication.

Statutory timetable

Phase 1 date Action
13 December 2018 Decision announced
18 October to 1 November 2018 Invitation to comment
18 October 2018 Launch of merger inquiry

Phase 1

CMA clearance decision

13 December 2018: The CMA has cleared the anticipated acquisition by Baxter International, Inc. of Hospira UK Limited’s compounding business and related assets.

Invitation to comment: Now closed

18 October 2018: The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.

Launch of merger inquiry

18 October 2018: The CMA announced the launch of its merger inquiry by notice to the parties.

Contact

Please send written representations about any competition issues to:

Joe McMahon
Competition and Markets Authority
Victoria House
Southampton Row
London
WC1B 4AD

joe.mcmahon@cma.gov.uk

Published 18 October 2018
Last updated 13 December 2018 + show all updates
  1. Clearance decision announced.
  2. First published.